当前位置: X-MOL 学术J. Crohns Colitis › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Immunological Variables Associated With Clinical and Endoscopic Response to Vedolizumab in Patients With Inflammatory Bowel Diseases.
Journal of Crohn's and Colitis ( IF 8.3 ) Pub Date : 2020-02-26 , DOI: 10.1093/ecco-jcc/jjaa035
Marina Coletta 1 , Moira Paroni 2, 3 , Maria Francesca Alvisi 4 , Matilde De Luca 4 , Eliana Rulli 4 , Stefano Mazza 1 , Federica Facciotti 5 , Georgia Lattanzi 5 , Francesco Strati 5 , Sergio Abrignani 2, 6 , Massimo Claudio Fantini 7 , Maurizio Vecchi 1, 8 , Jens Geginat 2 , Flavio Caprioli 1, 8
Affiliation  

Vedolizumab [VDZ] is a monoclonal antibody directed against the α4β7 integrin heterodimer, approved for patients with inflammatory bowel diseases [IBD]. This study aimed at identifying immunological variables associated with response to vedolizumab in patients with ulcerative colitis [UC] and Crohn’s disease [CD].

中文翻译:

与炎症性肠病患者对维多珠单抗的临床和内镜反应相关的免疫学变量。

维多珠单抗 [VDZ] 是一种针对 α4β7 整合素异二聚体的单克隆抗体,已被批准用于炎症性肠病 [IBD] 患者。本研究旨在确定与溃疡性结肠炎 [UC] 和克罗恩病 [CD] 患者对维多珠单抗的反应相关的免疫学变量。
更新日期:2020-02-26
down
wechat
bug